Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 11.81%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 11.81%.
Overvalued
The company’s latest PE is 26.39, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 117.02M shares, decreasing 7.30% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 7.88M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.36.